Stock Events

Stock Events

Protara Therapeutics 

$4.01
42
+$0.03+0.75% 16:03 Today

Statistics

Day High
4.11
Day Low
4
52W High
7.82
52W Low
2.97
Volume
13,458
Avg. Volume
-
Mkt Cap
236.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.57
-0.47
-0.38
-0.29
Expected EPS
-0.365714
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-57.44MNet Income

Analyst Ratings

26.50Average Price Target
The highest estimate is 27.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TARA. It's not an investment recommendation.
NVIDIA
13
NVDA
AMD
9
AMD
Microsoft
8
MSFT
Palantir Technologies
8
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences operates in similar therapeutic areas, including oncology, which competes with Protara's cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb offers a range of oncology treatments that directly compete with Protara's cancer drug pipeline.
Merck
MRK
Mkt Cap335.14B
Merck is known for its strong presence in the oncology market, competing with Protara's cancer therapies.
AMGEN
AMGN
Mkt Cap224.63B
Amgen focuses on innovative treatments in areas like oncology, posing competition to Protara's therapeutic approaches.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad portfolio of oncology drugs that compete with Protara's developments in cancer treatment.
Novartis
NVS
Mkt Cap286.78B
Novartis is a leading pharmaceutical company with a strong emphasis on oncology, competing with Protara's cancer therapies.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a growing oncology segment that competes with Protara's focus on cancer therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, competes in the oncology space, directly challenging Protara's market.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a significant presence in oncology, with a portfolio that competes with Protara's cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, known for its innovative biotechnology, competes in the development of cancer therapies similar to Protara's focus.

About

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Show more...
CEO
Jesse Shefferman
Employees
51
Country
United States
ISIN
US74365U1079
WKN
000A2P4JE

Listings

XNAS
US
TARA
STU
DE
1KPA.STU
MU
DE
1KPA.MU
F
DE
1KPA.F

0 Comments

Share your thoughts

FAQ

What is Protara Therapeutics stock price today?▼
The current price of TARA is $4.01 USD — it has increased by +0.75% in the past 24 hours. Watch Protara Therapeutics stock price performance more closely on the chart.
What is Protara Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Protara Therapeutics stocks are traded under the ticker TARA.
Is Protara Therapeutics stock price growing?▼
TARA stock has risen by +3.08% compared to the previous week, the month change is a -2.2% fall, over the last year Protara Therapeutics has showed a +31.48% increase.
What is Protara Therapeutics market cap?▼
Today Protara Therapeutics has the market capitalization of 236.97M
When is the next Protara Therapeutics earnings date?▼
Protara Therapeutics is going to release the next earnings report on October 29, 2026.
What were Protara Therapeutics earnings last quarter?▼
TARA earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.33 USD resulting in a -10.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protara Therapeutics revenue for the last year?▼
Protara Therapeutics revenue for the last year amounts to 0 USD.
What is Protara Therapeutics net income for the last year?▼
TARA net income for the last year is -57.44M USD.
How many employees does Protara Therapeutics have?▼
As of August 19, 2026, the company has 51 employees.
In which sector is Protara Therapeutics located?▼
Protara Therapeutics operates in the Health & Wellness sector.
When did Protara Therapeutics complete a stock split?▼
The last stock split for Protara Therapeutics was on January 10, 2020 with a ratio of 1:40.
Where is Protara Therapeutics headquartered?▼
Protara Therapeutics is headquartered in NEW YORK, United States.